Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238025 · ClinicalTrials.gov registry record · Phase 3
MVA-BN-RSV Vaccine Trial
A Phase 3 study, sponsored by Bavarian Nordic.
- Terminated
- Registry status
- Phase 3
- Development phase
- 20,419
- Enrollment target
NCT05238025 is a Phase 3 study that was terminated before completion, run by Bavarian Nordic. The registered enrollment target is 20,419 participants.
The verdict
NCT05238025, a Phase 3 study, was terminated before completion, sponsored by Bavarian Nordic.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 20,419 participants
- Enrollment target
Study Summary
Phase 3 randomized, double blind study comparing recombinant MVA-BN-RSV vaccine vs placebo for efficacy and safety in adults \>=60 years of age
Interventions
- BIOLOGICAL MVA-BN-RSV vaccine
- BIOLOGICAL Tris Buffered Saline (TBS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,419 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2023-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05238025
The ClinicalTrials.gov registry entry for NCT05238025 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 20,419 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MVA-BN-RSV vaccine is the first listed.
NCT05238025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05238025 about?
NCT05238025 is a clinical study titled "MVA-BN-RSV Vaccine Trial". Phase 3 randomized, double blind study comparing recombinant MVA-BN-RSV vaccine vs placebo for efficacy and safety in adults \>=60 years of age
What is the current status of trial NCT05238025?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 20,419 participants. The study started on 2022-04-19. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT05238025?
The interventions under investigation include: MVA-BN-RSV vaccine (BIOLOGICAL), Tris Buffered Saline (TBS) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05238025?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.